Company |
Drug |
Indication |
Allergan plc (Dublin) |
Juvederm Vollure XC |
Moderate to severe facial wrinkles and folds |
Apicore Inc. (subsidiary of Medicure Inc.; Winnipeg, Manitoba) |
Tetrabenazine tablets, 12.5 mg and 25 mg |
Involuntary movements (chorea) of Huntington's disease |
Astrazeneca plc (London) |
Qtern |
Type 2 diabetes |
EMD Serono Inc. (Rockland, Mass.; biopharmaceutical arm of Merck KGaA) |
Bavencio |
Metastatic Merkel cell carcinoma (12 years and older) |
Genentech Inc. (South San Francisco) |
Ocrevus |
Relapsing and primary progressive forms of multiple sclerosis |
Lexicon Pharmaceuticals Inc. (The Woodlands, Texas) |
Xermelo |
Carcinoid syndrome diarrhea |
Merck & Co. Inc. (Kenilworth, N.J.) |
Keytruda |
Refractory classical Hodgkin lymphoma |
Newron Pharmaceuticals SpA (Bresso, Italy) |
Xadago |
Parkinson's disease (PD) |
Novartis AG (Basel, Switzerland) |
Kisqali |
Breast cancer |
Regeneron Pharmaceuticals Inc. |
Dupixent |
Moderate to severe atopic dermatitis |
Serenity Pharmaceuticals LLC (Milford, Penn.) |
Noctiva nasal spray |
Nocturnal polyuria |
Shionogi & Co. Ltd. (Osaka, Japan) and Purdue Pharma LP (Stamford, Conn.) |
Symproic 0.2 mg tablets C-II |
Opioid-induced constipation in adults with chronic noncancer pain |
Tesaro Inc. (Waltham, Mass.) |
Zejula |
Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer |
Upsher-Smith Laboratories Inc., of Maple Grove, Minn. |
Qudexy XR capsules |
Migraine headache |